MaxCyte (NASDAQ: MXCT) is a clinical-stage biotechnology company aiming to improve therapeutic gene transfer, identifying more targeted ways to deliver drugs, and accelerating the drug discovery process by using new cell loading technologies.
Missing: MaxCyte's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: MaxCyte's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing MaxCyte
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
MaxCyte is included in 1 Expert Collection, including Biopharma Tech.
Latest MaxCyte News
Jan 5, 2023
MaxCyte Signs Strategic Platform License with Catamaran Bio to Support its CAR-NK Cell Therapy Programs MaxCyte’s Flow Electroporation® and ExPERT™ technologies to be used to enhance Catamaran’s TAILWIND® platform for novel CAR-NK cell therapies ROCKVILLE, Md, Jan. 3, 2023 /PRNewswire/ — MaxCyte, Inc. (Nasdaq: MXCT) (LSE: MXCT), a leading commercial cell-engineering company providing enabling platform technologies to advance innovative cell-based research, as well as next-generation cell therapeutic discovery, development and commercialization, today announced the signing of a strategic platform license (SPL) with Catamaran Bio, Inc. , a biotechnology company developing novel, off the-shelf chimeric antigen receptor (CAR)-NK cell therapies to treat a broad range of cancers, with a primary focus on solid tumors. Under the terms of the agreement, Catamaran obtains non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform. In return, MaxCyte will receive platform licensing fees and program-related revenue. “The ability to leverage synthetic biology to engineer cell therapies will help drive innovative solutions for solid tumor cancer treatment. At MaxCyte, we are passionate about driving the discovery, development and manufacturing of next-generation, cell-based medicines to tackle complex diseases and cancer,” said Doug Doerfler, President and CEO of MaxCyte. “We are excited to support Catamaran with the advancement of their pipeline of differentiated CAR-NK cell therapies into and through the clinic.” Catamaran is currently using synthetic biology and non-viral cell engineering to develop highly potent allogeneic, cryopreserved CAR-NK cell therapies capable of treating challenging cancers, including solid tumors, by combining new functional attributes with the inherent cancer-fighting properties of NK cells. The company has developed its TAILWIND® platform, an integrated suite of technologies, to engineer, expand and process NK cells into safe and effective, off-the-shelf cell therapy products for multiple cancer types. MaxCyte’s ExPERT™ instrument portfolio is the next generation of leading, clinically-validated electroporation technology for complex and scalable cell engineering. By delivering high transfection efficiency, seamless scalability and enhanced functionality, the ExPERT™ platform delivers the high-end performance essential to enabling the next wave of biological and cellular therapeutics. The Catamaran agreement is MaxCyte’s 19th SPL overall. About MaxCyte MaxCyte is a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support innovative, cell-based research. Over the past 20 years, we have developed and commercialized our proprietary Flow Electroporation® technology, which facilitates complex engineering of a wide variety of cells. Our ExPERT™ platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx®, STx® GTx® and VLx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. Learn more at maxcyte.com and follow us on Twitter and LinkedIn . About Catamaran Bio Catamaran Bio is developing novel, off-the-shelf chimeric antigen receptor (CAR)-NK cell therapies designed to treat a broad range of cancers, including solid tumors. The company’s proprietary capabilities enable it to harness the natural cancer-fighting properties of NK cells and enhance and tailor their effectiveness with the power of synthetic biology and innovative non-viral cell engineering. Catamaran uses its TAILWIND® platform , an integrated suite of technologies, to specifically address the end-to-end methods of engineering, processing and manufacturing NK cells and rapidly advance its pipeline of CAR-NK cell therapy programs. The company’s team combines experienced biopharmaceutical leadership with founding scientists who are pioneers in NK cell biology, engineering, manufacturing and clinical application. Catamaran is backed by leading financial and corporate investors, including SV Health Investors, Sofinnova Partners, Lightstone Ventures, Takeda Ventures, Astellas Venture Management, and the UMN Discovery Capital investment program. For more information, please visit catamaranbio.com and follow Catamaran on LinkedIn and @CatamaranBio on Twitter. CONTACT: US IR Adviser, Gilmartin Group, David Deuchler, CFA, +1 415-937-5400, [email protected] , US Media Relations, Spectrum Seismic Collaborative, Valerie Enes, +1 408-497-8568, [email protected] , Nominated Adviser and Joint Corporate Broker, Panmure Gordon, Emma Earl / Freddy Crossley, Corporate Broking, Rupert Dearden, +44 (0)20 7886 2500, UK IR Adviser, Consilium Strategic Communications, Mary-Jane Elliott, Chris Welsh, +44 (0)203 709 5700, [email protected] SOURCE MaxCyte
MaxCyte Frequently Asked Questions (FAQ)
When was MaxCyte founded?
MaxCyte was founded in 1999.
Where is MaxCyte's headquarters?
MaxCyte's headquarters is located at 22 Firstfield Road, Gaithersburg.
What is MaxCyte's latest funding round?
MaxCyte's latest funding round is IPO - II.
How much did MaxCyte raise?
MaxCyte raised a total of $22.35M.
Who are the investors of MaxCyte?
Investors of MaxCyte include Paycheck Protection Program, Maryland Department of Business & Economic Development, Tall Oaks Capital, Harbert Venture Partners, InterSouth Partners and 8 more.
Who are MaxCyte's competitors?
Competitors of MaxCyte include Cerecin, Cell Point, Array Biopharma, AngioChem, NGM Biopharmaceuticals, Threshold Pharmaceuticals, Pique Therapeutics, OxThera, BIND Therapeutics, Merrimack Pharmaceuticals and 14 more.
Compare MaxCyte to Competitors
OxThera is a biopharmaceutical company with products in late stage clinical development focusing on Primary and Secondary Hyperoxaluria. OxThera's intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria, and enzymes. Oxabact holds Orphan Drug designations in Europe and in the US for the treatment of primary hyperoxaluria.
Bionovo is a drug development company focusing on the discovery of novel pharmaceutical agents for cancer and women's health. The company's strategy is to develop new drugs that it derives from natural substances used therapeutically in non-western medical practice. Bionovo's first drug is entering phase II clinical testing for menopause, its second has completed phase I clinical testing for cancer, and these are followed by more than forty additional drug candidates that the company believes should provide Bionovo with a sustainable development pipeline of new chemical entities and botanicals.
Scientists at Epeius Biotechnologies have developed a targeted delivery system (TDS) that can transport genes or other therapeutic agents directly to diseased areas in the body. This pathotropic, or disease-seeking, technology has enabled the company to develop Rexin-G, a tumor-targeted, injectable gene delivery system that has demonstrated remarkable safety and single-agent efficacy in clinical trials internationally. Rexin-G is currently in clinical trials for pancreatic cancer in the U.S. ƒƒ‚ƒš‚" where it has achieved FDA orphan drug status ƒƒ‚ƒš‚" and has accelerated approval in the Philippines for the treatment of all solid tumors that are resistant to standard chemotherapy. The company's international clinical outreach with Rexin-G has enabled us to expedite further demonstrations that Rexin-G is highly active in a broad spectrum of chemo-resistant tumor types with efficacy and excellent safety profiles. The company are a biopharmaceutical company focused on expanding the therapeutic utility and commercialization of the company's pathotropic approach to disease treatment through internal development and commercialization of the company's oncology products and cancer vaccines, and through strategic partnerships in additional areas of oncology, immunology, cardiovascular, ocular, and wound healing applications, precision targeted diagnostics, and stem cell technologies.
Chroma Therapeutics is a biotechnology company founded to exploit the potential of chromatin biology for cancer drug discovery. Chroma is focused on the identification of anti-cancer agents that combine the efficacy of cytotoxics with the tumour cell selectivity of modern targeted therapeutics. Based in Oxford, UK, Chroma is developing a pipeline of anti-cancer drugs.
Pique Therapeutics is a biotechnology company focused initially on the treatment of cancer. Pique's lead product is a therapeutic vaccine for non-small cell lung cancer in Phase 2 clinical trials. Pique is also utilizing its therapeutic vaccine technology in additional areas of oncology, with products in pre-clinical stage for pancreatic, colorectal, and head and neck cancers.
Avestha Gengraine Technologies is a biotechnology & bioinformatics company, focusing on the convergence between food, pharmaceuticals and clinical genomics leading to preventive personalized medicine. . Avesthagen was founded by Dr. Villoo Morawala-Patell in 1998, on the premise that the time was ripe for India to establish its own research and discovery based biotechnology industry. Avesthagen aims to provide solutions for global challenges in agriculture & health problems in the areas of degenerative conditions, metabolic disorders and infectious diseases.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.